ArticleDepression and anxiety2019
A comparison of DSM-5 and DSM-IV agoraphobia in the World Mental Health Surveys.
Article in Depression and anxiety, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Genome-wide meta-analysis, functional genomics and integrative analyses implicate new risk genes and therapeutic targets for anxiety disorders.Nature human behaviour · 2024Pooled it
- Comorbidities in Obsessive-Compulsive Disorder Across the Lifespan: A Systematic Review and Meta-Analysis.Frontiers in psychiatry · 2021Pooled it
- Mobile App-Guided Exposure Therapy for Panic Disorder With and Without Agoraphobia: Randomized Controlled Trial.Journal of medical Internet research · 2025Trial
- Group Cognitive Behavioral Therapy With Virtual Reality Exposure Versus In-Vivo Exposure for Social Anxiety Disorder and Agoraphobia: Underpowered Results From the SoREAL Pragmatic Randomized Clinical Trial.JMIR mental health · 2025Trial
- Moderators of the cost-effectiveness of transdiagnostic CBT for anxiety disorders over an 8-month time horizon using a net-benefit regression framework.BMC health services research · 2023Trial
- Comorbidity of anxiety and dry eye disease: shared biomarkers and immune responses.Frontiers in immunology · 2026Article
- Association Between Psychiatric Comorbidity and Retention in Substance Use Disorder Treatment: Results From Multi-Site Randomized Controlled Trials of Pharmacological and Behavioral Interventions.Journal of dual diagnosis · 2026Article
- Examination of metacognitions and functionality in agoraphobia without comorbidities.BMC psychiatry · 2025Article
- Peer relationships, adolescent anxiety, and life satisfaction: a moderated mediation model in Turkish and syrian samples.European child & adolescent psychiatry · 2024Article
- Thirty-year trends of anxiety disorders among adolescents based on the 2019 Global Burden of Disease Study.General psychiatry · 2024Article
- Quality and Content Analysis: Can YouTube Videos on Agoraphobia Be Considered a Reliable Source?Cureus · 2023Article
- MiniQEEG and Neurofeedback in Diagnosis and Treatment of COVID-19-Related Panic Attacks: A Case Report.Brain sciences · 2022Article
- Where Sex Meets Gender: How Sex and Gender Come Together to Cause Sex Differences in Mental Illness.Frontiers in psychiatry · 2022Article
- Psychosocial and biological risk factors of anxiety disorders in adolescents: a TRAILS report.European child & adolescent psychiatry · 2021Article
- The Burden of Agoraphobia in Worsening Quality of Life in a Community Survey in Italy.Psychiatry investigation · 2021Article
- Anxiety disorders.Lancet (London, England) · 2021Review
- Twelve-month prevalence and severity of mental disorders in the Saudi National Mental Health Survey.International journal of methods in psychiatric research · 2020Article
- A comparison of DSM-5 and DSM-IV agoraphobia in the World Mental Health Surveys.Depression and anxiety · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 20 institutions in 25 countries.
Funding
Abstract
backgroundThe Diagnostic and Statistical Manual of Mental Disorders, version 5 (DSM-5) definition of agoraphobia (AG) as an independent diagnostic entity makes it timely to re-examine the epidemiology of AG. Study objective was to present representative data on the characteristics of individuals who meet DSM-IV criteria for AG (AG without a history of panic disorder [PD] and PD with AG) but not DSM-5 criteria, DSM-5 but not DSM-IV criteria, or both sets of criteria.
methodsPopulation-based surveys from the World Mental Health Survey Initiative including adult respondents (n = 136,357) from 27 countries across the world. The Composite International Diagnostic Interview was used to assess AG and other disorders.
resultsLifetime and 12-month prevalence estimates of DSM-5 AG (1.5% and 1.0%) were comparable to DSM-IV (1.4% and 0.9%). Of respondents meeting criteria in either system, 57.1% met criteria in both, while 24.2% met criteria for DSM-5 only and 18.8% for DSM-IV only. Severe role impairment due to AG was reported by a lower proportion of respondents who met criteria only for DSM-IV AG (30.4%) than those with both DSM-5 and DSM-IV AG (44.0%; χ
conclusionsThis first large survey shows that, compared to the DSM-IV, the DSM-5 identifies a substantial group of new cases with AG, while the prevalence rate remains stable at 1.5%. Severity and comorbidity are higher in individuals meeting DSM-5 AG criteria compared with individuals meeting DSM-IV AG criteria only.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.